Published in N Engl J Med on September 20, 2001
Mechanisms of Diabetic Kidney Disease in American Indians | NCT01878045
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA (2011) 4.70
Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2014) 4.30
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J (2010) 2.68
Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes. Health Serv Res (2006) 2.61
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Users' guide to detecting misleading claims in clinical research reports. BMJ (2004) 2.55
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis (2012) 2.51
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Cell biology and pathology of podocytes. Annu Rev Physiol (2011) 2.42
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol (2005) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 2.24
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Population based screening for chronic kidney disease: cost effectiveness study. BMJ (2010) 2.19
Recommendations from the Canadian Diabetes Association. 2003 guidelines for prevention and management of diabetes and related cardiovascular risk factors. Can Fam Physician (2004) 2.18
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (2009) 2.17
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2014) 2.16
Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract (2006) 2.10
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol (2011) 2.07
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A (2008) 2.06
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
2009 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2009) 2.03
AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab (2011) 2.03
Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol (2008) 1.93
Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int (2013) 1.93
Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int (2012) 1.92
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol (2013) 1.91
CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis (2011) 1.88
Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis (2009) 1.84
The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med (2008) 1.83
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
The growth of acute kidney injury: a rising tide or just closer attention to detail? Kidney Int (2014) 1.80
Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia (2011) 1.80
Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.79
Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care (2014) 1.79
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol (2013) 1.77
Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol (2010) 1.76
Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant (2012) 1.75
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol (2008) 1.71
Oxidative stress in diabetic nephropathy. Curr Med Chem (2010) 1.70
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Development and results of a kidney disease knowledge survey given to patients with CKD. Am J Kidney Dis (2010) 1.64
Histopathology of diabetic nephropathy. Semin Nephrol (2007) 1.60
Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens (2010) 1.60
A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. Clin J Am Soc Nephrol (2011) 1.58
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol (2007) 1.55
Gq signaling causes glomerular injury by activating TRPC6. J Clin Invest (2015) 1.54
Preventing diabetes-related morbidity and mortality in the primary care setting. J Natl Med Assoc (2002) 1.53
Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia (2011) 1.53
The kidney in type 2 diabetes therapy. Rev Diabet Stud (2011) 1.50
Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int J Clin Pract (2008) 1.49
Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes (2010) 1.48
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Clin Exp Nephrol (2006) 1.46
Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res (2015) 1.45
Diabetes and Cause-Specific Mortality in Mexico City. N Engl J Med (2016) 1.44
Endothelial dysfunction as a potential contributor in diabetic nephropathy. Nat Rev Nephrol (2010) 1.43
Diabetic nephropathy. Diabetol Metab Syndr (2009) 1.43
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin Proc (2011) 1.43
Effects of dual blockade of the renin-angiotensin system on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy and hypertension in the ORIENT: a post-hoc analysis (ORIENT-Hypertension). Hypertens Res (2013) 1.42
The renin-aldosterone axis in kidney transplant recipients and its association with allograft function and structure. Kidney Int (2013) 1.42
Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrol Dial Transplant (2015) 1.42
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med (2016) 1.40
Irbesartan Ameliorates Diabetic Nephropathy by Suppressing the RANKL-RANK-NF-κB Pathway in Type 2 Diabetic db/db Mice. Mediators Inflamm (2016) 1.40
Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39
Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol (2008) 1.36
Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol (2006) 1.35
eGFR: is it ready for early identification of CKD? Clin J Am Soc Nephrol (2008) 1.35
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Complex splicing patterns of RNAs from the early regions of adenovirus-2. J Mol Biol (1979) 7.53
Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med (1996) 5.46
The Heidelberg classification of renal cell tumours. J Pathol (1997) 5.36
Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA (2001) 4.75
Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology (1999) 4.49
Mapping of late adenovirus genes by cell-free translation of RNA selected by hybridization to specific DNA fragments. Proc Natl Acad Sci U S A (1975) 4.35
A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med (1992) 4.33
A map of cytoplasmic RNA transcripts from lytic adenovirus type 2, determined by electron microscopy of RNA:DNA hybrids. Cell (1977) 4.26
The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med (1999) 4.03
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Tracking of blood lipids and blood pressures in school age children: the Muscatine study. Circulation (1978) 3.59
Location and identification of the genes for adenovirus type 2 early polypeptides. Cell (1976) 3.58
Cell-free synthesis of adenovirus 2 proteins programmed by fractionated messenger RNA: a comparison of polypeptide products and messenger RNA lengths. Proc Natl Acad Sci U S A (1974) 3.52
Control of adenovirus early gene expression: a class of immediate early products. Cell (1980) 3.41
Identification of the gene and mRNA for the adenovirus terminal protein precursor. Cell (1981) 3.39
Sodium. Lancet (1998) 3.38
The nephrotic syndrome. N Engl J Med (1998) 3.22
Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int (1999) 3.09
Childhood risk factors for high adult blood pressure: the Muscatine Study. Pediatrics (1989) 3.06
Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ. Am J Physiol (1990) 3.01
Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet (1998) 2.98
Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis (1990) 2.91
Further mapping of late adenovirus genes by cell-free translation of RNA selected by hybridization to specific DNA fragments. Cell (1977) 2.78
Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex. J Exp Med (1975) 2.78
Proteins and messenger RNAs of the transforming region of wild-type and mutant adenoviruses. J Mol Biol (1980) 2.73
A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem (1995) 2.71
The specific selection of recirculating lymphocytes by antigen in normal and preimmunized rats. J Exp Med (1972) 2.66
The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54
Specific unresponsiveness of recirculating lymphocytes ater exposure to histocompatibility antigen in F 1 hybrid rats. Nat New Biol (1971) 2.50
Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis (2001) 2.42
Hantavirus infection presenting as acute renal failure. Lancet (1990) 2.40
Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant (2000) 2.38
The ankle injury--indications for the selective use of X-rays. Injury (1983) 2.35
Tubular epithelial-myofibroblast transdifferentiation in progressive tubulointerstitial fibrosis in 5/6 nephrectomized rats. Kidney Int (1998) 2.35
Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia. The Muscatine Study. JAMA (1990) 2.34
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Factors affecting the relationship between childhood and adult cholesterol levels: the Muscatine Study. Pediatrics (1988) 2.31
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Is there a Persian Gulf War syndrome? Evidence from a large population-based survey of veterans and nondeployed controls. Am J Med (2000) 2.23
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int (2006) 2.22
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
Osmotic and nonosmotic control of vasopressin release. Am J Physiol (1979) 2.18
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int (2006) 2.18
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17
The rising tide of endstage renal failure from diabetic nephropathy type II--an epidemiological analysis. Nephrol Dial Transplant (1995) 2.06
[Study on the antigenic relationships between the group O:54 and other groups O of Salmonella]. Ann Inst Pasteur (Paris) (1971) 2.05
Group A streptococcal necrotizing fasciitis complicating primary varicella: a series of fourteen patients. Pediatr Infect Dis J (1995) 2.04
Adenovirus type 2 early proteins: assignment of the early region 1A proteins synthesized in vivo and in vitro to specific mRNAs. Virology (1981) 2.04
Tissue culture of isolated glomeruli in experimental crescentic glomerulonephritis. J Exp Med (1978) 2.02
Insulin resistance associated with lower rates of weight gain in Pima Indians. J Clin Invest (1991) 2.02
Coronary heart disease risk factors in school children: the Muscatine study. J Pediatr (1975) 2.02
Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol (1997) 2.00
Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest (1989) 1.98
Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol (1999) 1.95
Enhanced differential synthesis of proteins in a mammalian cell-free system by addition of polyamines. J Biol Chem (1975) 1.93
Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Neurology (1999) 1.93
The macrophagen in human rapidly progressive glomerulonephritis. Lancet (1976) 1.88
OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation? Am J Transplant (2008) 1.88
The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med (1997) 1.86
Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. J Clin Invest (1975) 1.85
Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int (2007) 1.83
A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82
Frequency, risk factors, anatomy, and course of unilateral neglect in an acute stroke cohort. Neurology (2004) 1.81
Glomerulonephritis. Lancet (2005) 1.81
Jugular bulb saturation and cognitive dysfunction after cardiopulmonary bypass. Ann Thorac Surg (1994) 1.80
Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.79
Impending paradoxical embolism. Arch Intern Med (1998) 1.79
Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int (1998) 1.77
Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart (2003) 1.76
Conditional lethal mutants of adenovirus type 2-simian virus 40 hybrids. II. Ad2+ND1 host-range mutants that synthesize fragments of the Ad2+ND1 30K protein. J Virol (1976) 1.76
Mechanism of the antidiuretic effect associated with interruption of parasympathetic pathways. J Clin Invest (1972) 1.72
Normal blood pressure and the evaluation of sustained blood pressure elevation in childhood: the Muscatine study. Pediatrics (1978) 1.72
Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases. Nephrol Dial Transplant (1998) 1.71
PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int (2001) 1.69
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int (2007) 1.67
Serum C3 levels are diagnostically more sensitive and specific for systemic lupus erythematosus activity than are serum C4 levels. The Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1991) 1.66
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
Characterization of a fused protein specified by the adenovirus type 2-simian virus 40 hybrid Ad2+ND1 dp2. J Virol (1979) 1.65
C3b inactivator of man. 3. Further purification and production of antibody to C3b INA. J Immunol (1972) 1.64
Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol (2006) 1.61
Disturbed calcium metabolism in subjects with elevated diastolic blood pressure. Clin Investig (1992) 1.61
Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int (1998) 1.61
Leukocyte analysis using monoclonal antibodies in human glomerulonephritis. Kidney Int (1987) 1.60
Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int (2001) 1.60
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract (2004) 1.60
Altered water metabolism in tuberculosis: role of vasopressin. Am J Med (1990) 1.60
The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. J Biol Chem (1997) 1.60
Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins. Thromb Haemost (1984) 1.59
"Beer potomania" in non-beer drinkers: effect of low dietary solute intake. Am J Kidney Dis (1998) 1.59
Early cellular events in a systemic graft-vs.-host reaction. I. The migration of responding and nonresponding donor lymphocytes. J Exp Med (1975) 1.57